@misc{indiciaecd5af4099b5a,
  title = {The STAMP inhibitor asciminib is a new treatment option for ABL-rearranged ALL revealing a novel role for the 5' fusion partner in determining drug response},
  author = {Eadie, L. N. and McDougal, D. P. and Lagonik, E. and Schutz, C. E. and Conlin, T. S. and Page, E. C. and Rehn, J. and Bruning, J. B. and Moore, A. S. and Yeung, D. T. and Hughes, T. P. and White, D. L.},
  year = {2025},
  doi = {10.1101/2025.05.06.652078},
  url = {https://www.biorxiv.org/content/10.1101/2025.05.06.652078v1},
  note = {Source identifier: 10.1101/2025.05.06.652078}
}